info@mail.ucallm.com
From Progenitor Identity to Vascular Remodeling — Empowering Comprehensive Investigation of EPC Differentiation, Angiogenic Signaling, and Tumor Vascularization with Validated Antibody Solutions
Endothelial progenitor cells (EPCs) represent a critical population involved in vascular repair, neovascularization, and pathological angiogenesis. Emerging evidence indicates that EPC biology extends beyond classical endothelial regeneration, involving dynamic transitions between monocyte-derived progenitor states, endothelial lineage commitment, inflammatory regulation, and vascular remodeling within the tumor microenvironment.
EPC differentiation and angiogenic function are orchestrated through integrated molecular networks, including:
· Endothelial lineage specification and surface marker transition
· VEGF-driven angiogenic signaling pathways
· Notch-mediated endothelial fate determination
· Chemokine-controlled progenitor recruitment and vascular niche formation
· Extracellular matrix remodeling and vessel maturation
· Inflammatory macrophage–endothelial communication
Our validated antibody portfolio supports comprehensive EPC and angiogenesis research workflows, enabling researchers to characterize:
· EPC identification and endothelial differentiation status
· Monocyte-to-endothelial transition and progenitor remodeling
· Pro-angiogenic signaling activation
· Endothelial fate specification pathways
· Tumor angiogenic niche formation and vascular remodeling
· Metabolic regulation of EPC differentiation and angiogenic capacity
EPC & Angiogenesis Biomarker Antibody Portfolio
— Comprehensive Solutions for EPC Identification, Endothelial Differentiation, and Vascular Remodeling Analysis
EPC-mediated vascular formation requires coordinated regulation of progenitor recruitment, endothelial specification, angiogenic activation, and tissue remodeling.
Our antibody portfolio provides validated tools for profiling key biological transitions from circulating progenitor cells to functional endothelial structures.
Research Focus | Representative Biomarkers | Research Applications |
EPC Identity & Endothelial Differentiation | CD14, CD31/PECAM1, VE-Cadherin/CD144, VEGFR2/KDR, CD146, vWF, CD34 ,CD133 | Identification of EPC populations, monitoring monocyte-to-endothelial differentiation, endothelial lineage confirmation |
Monocyte Recruitment & Progenitor Mobilization | CCR2, CXCR4, CD68, CD80, CD163 | Analysis of inflammatory recruitment, myeloid-derived EPC populations, vascular niche formation |
VEGF Angiogenic Signaling Axis | VEGFA, VEGFR1/FLT1, VEGFR2/KDR, VEGFB ,PlGF | Investigation of VEGF-driven endothelial activation, angiogenic signaling, and vessel formation |
Endothelial Growth Factor Networks | FGF2, FGFR1/2, ANGPT1 | Characterization of endothelial proliferation, vessel maturation, and vascular stabilization |
ECM Remodeling & Vessel Sprouting | Fibronectin (FN), MMP9 | Analysis of extracellular matrix remodeling, endothelial migration, and capillary sprouting |
Inflammatory Angiogenic Regulation | TNF-α, IL-8, MCP1/CCL2, MIF, CSF1 | Investigation of inflammatory cytokine-mediated angiogenesis and tumor vascular remodeling |
Notch Endothelial Fate Regulation | Notch1, Notch2, DLL1, HES1, HEY1, HEY2,DLL4 | Analysis of endothelial specification, vascular differentiation, and angiogenic maturation |
Metabolic Regulation of EPC Function | ALDH, NOX2, NOX4, SOD2, PRDX1 , 8-OHdG | Investigation of metabolic reprogramming controlling EPC differentiation and angiogenic capacity |
Integrated EPC–Angiogenesis Regulatory Landscape
— Mapping the Molecular Hierarchy from Progenitor Activation to Functional Vascular Formation
Endothelial progenitor cell (EPC)-mediated angiogenesis is governed by a coordinated regulatory landscape integrating microenvironmental signals, progenitor recruitment, endothelial lineage specification, angiogenic signaling, and vascular maturation programs.
This integrated network enables researchers to investigate how EPCs respond to physiological and pathological stimuli, acquire endothelial identity, and contribute to vascular remodeling during tissue regeneration, tumor angiogenesis, and vascular disease progression.
Regulatory Network | Key Molecular Drivers | Representative Biomarkers |
Hypoxia & Tissue Stress Response Network | Hypoxia, inflammatory signals, tissue injury, tumor-derived factors | HIF-1α, ROS markers, NRF2 |
Chemokine-Mediated Progenitor Trafficking Network | CCL2/CCR2 axis, CXCR4 signaling, CSF1 pathway | CCL2, CCR2, CXCR4, CSF1 |
Myeloid-to-Endothelial Differentiation Network | Progenitor remodeling and endothelial commitment programs | CD14, ALDH, CD68, CD31, CD146 |
VEGF–Notch–FGF Regulatory Axis | VEGF signaling, Notch-dependent endothelial fate control, growth factor activation | VEGFA, VEGFR1, VEGFR2, Notch1, DLL1, HEY2, FGF2 |
Endothelial Migration & Sprouting Network | Cytoskeletal remodeling, extracellular matrix interaction, angiogenic stimulation | CD31, VE-Cadherin, MMP9, Fibronectin |
Vascular Integrity Network | Endothelial junction formation, pericyte interaction, vessel stabilization | VE-Cadherin, ANGPT1, vWF |
Tumor–Immune–Vascular Crosstalk Network | Inflammatory cytokines, macrophage signaling, tumor angiogenic niche | TNF-α, IL-8, MIF, CD68, CD163 |
Featured EPC & Angiogenesis Research Panels
Endothelial progenitor cell (EPC) biology involves dynamic transitions from circulating progenitor recruitment to endothelial lineage commitment and functional vessel formation. Comprehensive biomarker profiling enables researchers to dissect the molecular mechanisms controlling EPC mobilization, endothelial differentiation, angiogenic signaling, vascular maturation, and pathological neovascularization.
Our validated antibody panels provide multi-dimensional solutions for investigating vascular development, tissue repair, tumor angiogenesis, and therapeutic resistance mechanisms.
n EPC Identification & Endothelial Commitment Panel—Defining progenitor transition toward endothelial lineage
Key Markers
CD14 | CD31 | VE-Cadherin | VEGFR2 | CD146 | vWF | CD34 | CD133 |
n Tumor Angiogenic Microenvironment Panel—Understanding immune–vascular interactions in cancer progression
Key Markers
CCR2 | CXCR4 | CD68 | CD163 | CSF1 |
MCP1 | MIF | TNF-α | IL-8 | CD80 |
n Vascular Remodeling & ECM Interaction Panel—Analyzing endothelial migration and vessel formation
Key Markers
Fibronectin | MMP9 | VEGFA | ANGPT1 | CD31 | VE-Cadherin |
n EPC Metabolic Adaptation & Functional Regulation Panel—Revealing Metabolic Programs Supporting Endothelial Progenitor Function
Key Markers
ALDH | HIF-1α | NRF2 | SOD2 | DRP1 | PGC-1α | GLUT1 |
Why Researchers Choose Our EPC & Angiogenesis Antibody Solutions
Integrated Biomarker Solutions for Decoding EPC Identity, Regulatory Networks, and Vascular Remodeling Mechanisms
Our validated antibody portfolio enables comprehensive investigation of the entire angiogenic cascade — from EPC mobilization and endothelial commitment to functional vessel formation and pathological vascular remodeling.
Research Challenge | Our Solution |
How do EPCs acquire endothelial identity? | EPC Identity & Endothelial Commitment Network CD14 → CD31/PECAM1 → VE-Cadherin → VEGFR2 → CD146 → vWF Enables tracking of progenitor-to-endothelial transition and lineage commitment |
How are endothelial fate decisions regulated? | Endothelial Specification Regulatory Network VEGF–Notch–FGF signaling axis VEGFA, VEGFR1/FLT1, VEGFR2/KDR, Notch1/2, DLL1, HES1, HEY1/2 Supports analysis of endothelial differentiation, proliferation, and vessel patterning |
How are EPCs recruited into vascular niches? | Chemokine Recruitment Network CCR2 / CXCR4 / CCL2(MCP-1) axis Enables investigation of progenitor mobilization, inflammatory recruitment, and vascular niche formation |
How does the tumor microenvironment promote angiogenesis? | Tumor Angiogenic Microenvironment Network TNF-α, IL-8, MIF, CSF1, CD68, CD163 Supports immune–vascular crosstalk and tumor-associated angiogenesis studies |
Key reference
1. Lopes-Coelho F., et al. (2020). Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis. Cells. 9:107.
2. Plein A., et al. (2018). Erythro‑myeloid progenitors contribute endothelial cells to blood vessels. Nature. 562:223‑228.
3. Liu Y., et al. (2018). Innate immune signaling promotes a glycolytic switch that is required for monocyte trans‑differentiation to endothelial lineage. Circulation. 138:1413‑1426.
4. Olingy C.E., Dinh H.Q., Hedrick C.C. (2019). Monocyte heterogeneity and functions in cancer. Journal of Leukocyte Biology. 106:309‑322.
5. Nagarkoti S., et al. (2026). Endothelial Drp1 integrates VEGF‑induced redox signaling with glycolysis through cysteine oxidation to drive angiogenesis. Nature Communications. 17:2867.
6. Vasudev N.S., Reynolds A.R. (2014). Anti‑angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis. 17:471‑494.
7. Ribatti D. (2026). Molecular Mechanisms of Vasculogenesis in Human Cancers: From Developmental Pathways to Tumor Vascular Remodeling and Therapeutic Targeting. Biology. 15:1362.